Newsroom | 5850 results

ALPHARETTA, Ga.--(BUSINESS WIRE)--National Vision Holdings, Inc. (NASDAQ: EYE), one of the largest optical retail companies in the United States, announced today that its annual scholarship program is open for entries, offering eligible optometry students the opportunity to win up to $7,500.This year’s scholarship program challenges students to explore the topic of, “Balancing Innovation and Human Connection.” Third- and fourth-year optometry students are invited to submit written or video essay...

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announced two presentations of data for STK-002 at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting, taking place October 9-12 in New Orleans. STK-002 represents a novel approach to Autosomal Dominant Optic Atrophy (ADOA), the most common inherited optic nerve disorder, by targeting...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that Bausch + Lomb Board of Directors Chairman Thomas J. Appio has been appointed interim chief executive officer, effective immediately. Appio will continue to serve as CEO of Bausch Health while assuming leadership of Bausch + Lomb. Appio was appointed chairman of the Bausch + Lomb Board of Dir...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of one-year results from the pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig (MK-3000, formerly EYE103), an investigational, potentially first-in-class tetravalent, tri-specific antibody designed to activate the Wingless-related integration site (Wnt) pathway, for the treatment of diabetic macular edema (DME). Results were presented today at the...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new one-year data from the Phase III MEERKAT and SANDCAT studies evaluating investigational vamikibart compared with a sham procedure that mimics intravitreal (IVT) injections in adults with uveitic macular edema (UME). Across both studies, data continue to support the potential for rapid and sustained improvements in vision and reductions in macular thickness (swel...

ANN ARBOR, Mich.--(BUSINESS WIRE)--Sling Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the first and only late-stage oral small-molecule therapy for thyroid eye disease (TED), today announced the presentation of efficacy, safety and new durability results from its Phase 2b/3 LIDS trial of linsitinib in adults with moderate to severe active TED. The data were highlighted in an oral presentation and in a poster session at the American Society of Ophthalmic Plastic and...

BROOKLYN, New York--(BUSINESS WIRE)--Carrot (formerly Virtual Field), the most widely used VR testing and diagnostic platform in eye care, today announced an agreement to acquire GreenMan Vision, Inc., the company behind InSightVR. The deal will add intraocular lens (IOL) simulation for cataract surgery to the Carrot Platform and expand Carrot from vision diagnostics into vision simulation. “For more than 40 years, patients have dreaded the visual field test,” said Jeremy Barlow, CEO of Carrot....

STUART, Fla.--(BUSINESS WIRE)--Stuart Therapeutics Inc., a late-stage biopharmaceutical company developing a new class of therapeutics designed to treat eye diseases by repairing helical collagen, today announced it has submitted an investigational new drug application amendment to the U.S. Food and Drug Administration to study its lead candidate, ST-100 (vezocolmitide), in corneal wound healing. The planned proof-of-concept study would mark ST-100's first expansion beyond dry eye disease and co...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced positive topline results from the Phase 4 prospective, randomized, controlled clinical trial (GLK-101-04) evaluating iDose® TR administered in conjunction with cataract surgery compared to cataract surgery alone in patients with open-angle glaucoma (OA...

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM), a leading consumer healthcare company focused on helping people achieve their best health, today announced improved Star Ratings for 2027, highlighted by 95% of its Medicare Advantage members being enrolled in plans rated 4.0 stars or above by the Centers for Medicare and Medicaid Services (CMS). Additionally, 42% of Humana Medicare Advantage members are enrolled in 4.5-star plans for 2027.“We’re extremely proud of these Star Ratings. Th...